TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. TF Capital aims to capture opportunities in the Chinese life sciences market. The company specializes in biotechnology, therapeutics & pharmaceuticals, drug delivery, medical devices & instruments and medical service. TF Capital focuses on preclinical and early clinical-stage companies. Their approach includes active management and long-term commitment.
TF Capital along with Tigermed and Yingke PE led Series C round financing for EOC Pharma, an oncology-focused biopharmaceutical company that secured nearly 500 million yuan ($71 million) in December 2019.
Documentaries, videos and podcasts